secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104998
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced
--------------------------------------------------------------------------------

- Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.
- Cash, equivalents and marketable securities fell to $10.2M as of June 30, 2025 from $27.6M at Dec 31, 2024.
- Entered research collaboration with Chugai for two undisclosed molecules; bioequivalence to subcutaneous delivery confirmed.
- Warrant inducement transaction yielded $4.3M gross proceeds; registered direct offering raised $3.0M.
- Phase 1 trial of oral GLP-1/GLP-2 agonist RT-114 for obesity expected to start H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/0000950170-25-104998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer